Incyte Genomics Inc (INCY) — Analysis Summary
Incyte Genomics Inc (INCY) has a market cap of $25.89B with year-over-year revenue growth of +21.2%. Net margin stands at 25.0%. The stock trades at a P/E ratio of 18.1.
Key Takeaways
- Revenue changed +21.2% year-over-year
- Net margin of 25.0%
- P/E ratio of 18.1
Compared to other companies in the SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH sector, INCY posted revenue growth of +21.2% and trades at a P/E of 18.1.
Incyte Genomics Inc (INCY)
UPDATED — ET · MARKET DATA POLYGON · FINANCIALS SEC EDGAR
Red Flags & WarningsWatch List
Some caution signals are active and should be weighed alongside the valuation work.
Gross margin at 92.5% — verify: very few businesses sustain >90% gross margin outside pure software/IP
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes an array of oncology and dermatology programs.
Sector
SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH
Employees
2,844
Headquarters
WILMINGTON, DE
Exchange
XNAS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.